Olatunji Alese, MD
Enriched profileProfessor, Department of Hematology and Medical Oncology, Emory University School of Medicine · Emory University
Olatunji Alese is Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine at Emory University. OpenAlex indexes 324 publications with 4,401 citations (h-index 34); ClinicalTrials.gov lists 11 registered studies with this person as an investigator.
Data verified 10 Oct 2026
Overview
Updated 16 Oct 2026
Olatunji Alese, M.D., is Professor, Department of Hematology and Medical Oncology, Emory University School of Medicine. The public record shows 324 publications with 4,401 citations (h-index 34), centered on Cancer Immunotherapy and Biomarkers, Pancreatic and Hepatic Oncology Research, Colorectal Cancer Treatments and Studies. It also documents an investigator role on 11 registered clinical trials, industry payments reported by 19 companies.
- Most recent indexed publication: 2026 · JCO precision oncology
- Top research focus: Cancer Immunotherapy and Biomarkers
- 11 registered trials on ClinicalTrials.gov
- Open Payments reporting from 19 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 29 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 75.
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 11 registered studies on ClinicalTrials.gov. The most recent:
Industry payments
Updated 16 Oct 2026
19 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Incyte CorporationProgram year20259 payments
- Exelixis Inc.Program year202511 payments
- E.R. Squibb & Sons, L.L.C.Program year20252 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
36.4%Serotonin-3 Receptor Antagonist13.6%Ondansetron Hcl100%Part D≥11 patientsAntidiarrheal microorganisms12.5%Creon100%Part D<11 patients+ 1 more class in this area
Nervous system
27.3%Phenothiazine15.3%Prochlorperazine Maleate100%Part D≥19 patientsOpioid Agonist11.9%Oxycodone Hcl100%Part D≥15 patientsCancer & immunology
21%Kinase inhibitor11.4%Imatinib Mesylate100%Part D<11 patientsNucleoside Analog Antiviral9.7%Lonsurf100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Congress activity
Updated 16 Oct 2026
117 congress contributions (2007–2026) across AACR, ASCO, ASTRO, ESMO per OpenAlex. The most recent:
- Abstract 1192: Survival trends in the management of carcinoid heart disease among patients with neuroendocrine tumors.
AACR Annual Meeting
AACR2026Co-author - A phase 1, first-in-human (FIH), dose-escalation and dose-optimization study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of CBI-1214 T-cell engager in participants with advanced or metastatic microsatellite-stable (MSS)/microsatellite instability–low (MSI-L) colorectal cancer (CRC).
ASCO Annual Meeting
ASCO2026Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study.
JCO precision oncology
Clinical Trial2026 - Survival trends in the management of carcinoid heart disease among patients with neuroendocrine neoplasms.
Cardio-oncology (London, England)
Article2026 - Reply to: Delta-Like Ligand 3 Expression Across Lung Neuroendocrine Subtypes: Interpreting Response in Small Cell Lung Cancer and Beyond.
Journal of clinical oncology
Article2026
Most-cited works
by citation count (OpenAlex)- 01
- 02
- 03
- 04Appendiceal Mucinous Neoplasms: Diagnosis and ManagementArticle266 citations2017
- 05
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/olatunji-alese-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Editorial & leadership roles
journal and society appointments- Former Advisory Group member
ASCO International Affairs Committee
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- Fellow
American Society of Clinical Oncology (FASCO)
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →winshipcancer.emory.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- ECOG Foundation/Paul Carbone
MD Fellowship award
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Secondary affiliations
appointments beyond the home institution- Director of Gastrointestinal Oncology
Winship Cancer Institute of Emory University
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗ - Member
Discovery and Developmental Therapeutics Research Program, Winship Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →winshipcancer.emory.edu ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Keith Delman, MD
Emory University
James Lah, MD
Emory University
John Puskas, MD
Emory University
Craig Hofmeister, MD
Emory University
Eric Van Cutsem, MD, PhD
University Hospitals Leuven (UZ Leuven)
Josep Tabernero, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Jaffer Ajani, MD
The University of Texas MD Anderson Cancer Center
Charles Fuchs, MD, MPH
Tubulis GmbH